Shares of Cadila Healthcare gained 2.6 percent intraday on February 10 after receiving Establishment Inspection Report from the US health regulator for Ahmedabad unit.
The topical manufacturing facility had completed the USFDA audit during December 16-20, 2019.
After the inspection, the plant received zero 483 observations.
Hence, the facility located at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying successful closure of the audit, Cadila said in its BSE filing.
The stock was quoting at Rs 276.60, up Rs 1.30, or 0.47 percent on the BSE at 1518 hours IST.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!